A recent article in The Atlantic discusses the risk of 23andMe selling its vast stockpile of DNA data on 15 million individuals: 23andMe is not doing well. Its stock is on the verge of being delisted. It shut down its in-house drug-development unit last month, only the latest in several rounds of layoffs. Last week, the entire […]
Bankruptcy Sale of DNA Data: From Toysmart to 23andMe
